Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: f
View:
• Confirmed Parkinson's Disease diagnosis.
• Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
• Age (50 to 80 years of age).
• Ability to read and write in English.
Locations
United States
Pennsylvania
UPMC Presbyterian Hospital
RECRUITING
Pittsburgh
Contact Information
Primary
Pravat K MANDAL, PHD
mandalpk@pitt.edu
4126999561
Backup
Nazia Pillar, M.S
naa430@pitt.edu
878-670-3123
Time Frame
Start Date: 2026-01-15
Estimated Completion Date: 2027-11-27
Participants
Target number of participants: 12
Treatments
Experimental: Gamma - Glutamylcysteine
Patients will receive GGC tablet 400mg orally twice a day (morning and in the afternoon).
Related Therapeutic Areas
Sponsors
Collaborators: Waste Connections Inc
Leads: Pravat Mandal